Palisade Bio, Inc. PALI
Palisade Bio, Inc. (Nasdaq: PALI) is a GI/hepatology drug developer. Its lead program, PALI-2108, is in Phase 1 for ulcerative colitis (UC) and Crohn's disease (incl. fibrostenotic Crohn's, FSCD). Its next catalyst on record is PALI-2108 ASCENTRA-UC: Initiate patient enrollment (first patient) (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PALI-2108 ASCENTRA-UC — Initiate patient enrollment (first patient) (H2 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PALI-2108 ASCENTRA-UC | moderately-to-severely active UC | small molecule | Phase 2 |
| PALI-2108 ASCENTRA-CD | moderately-to-severely active Crohn's disease | small molecule | Phase 2 |
| PALI-2108 Phase 1/1b (healthy volunteers, UC and FSCD cohorts) | UC, fibrostenotic Crohn's disease | small molecule | Phase 1 |
| LB1148 (China, Newsoara co-development) | gastrointestinal | protein/peptide | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.